Cost-effectiveness analysis of the empirical antifungal strategy in oncohaematological patients

• Published in: Farmacia hospitalaria Vol. 32; no. 1; p. 7
• Main Authors: Romá-Sánchez, E, Poveda-Andrés, J L, García-Pellicer, J, Salavert-Lletí, M, Jarque-Ramos, I
• Format: Journal Article
• Language: Spanish
• Published: Spain 01.01.2008
• Subjects: Antifungal Agents - economics; Antifungal Agents - therapeutic use; Cost-Benefit Analysis; Empirical Research; Female; Humans; Leukemia - economics; Leukemia - epidemiology; Male; Middle Aged; Mycoses - drug therapy; Mycoses - economics; Mycoses - epidemiology; Prospective Studies; Pyrimidines - economics; Pyrimidines - therapeutic use; Retrospective Studies; Triazoles - economics; Triazoles - therapeutic use; Voriconazole
• ISSN: 1130-6343

Observational study performing a cost-effectiveness analysis of the empirical antifungal strategy in high-risk oncohaematological patients, from the hospital perspective and with an average time horizon of 10.8 days of treatment. Data gathered: effectiveness, purchase costs and other costs (diagnostic tests, hospitalisation, and second-line antifungal therapy). A total of 107 patients were analysed, 115 invasive fungal infection sub-episodes and 138 empirical treatments. The effectiveness and average cost/treatment were: voriconazole 88% and 20,108.8 euro, caspofungin 68% and 49,067.7 euro, Amphotericin B Lipid Complex (ABLC) 58% and 30,375.2 euro, and Amphotericin B Liposome (AB-L) 50% and 38,234.5 euro. The first tree designed shows voriconazole as the dominant option, although there are few case studies. The second tree selects ABLC in comparison to AB-L and caspofungin, with an average CE of 52,371 euro, the nearest figure to the established availability to pay (50,000 euro). The sensitivity analysis evaluates the most influential parameters. The variation in the cost of purchasing do not modify the sense of the analysis, and the modification of 25% in other costs for caspofungin reverses the ratio, making this the most cost-effective option. The ICE indicates that using voriconazole instead of caspofungin saves 144,794 euro. With regard to caspofungin, ABLC increases the cost by 186,925 euro, a deceptive figure influenced by a level of effectiveness that is not very different; and AB-L increases the cost by 60,184 euro. The analysis provides relevant information from the perspective of clinical practice in spite of the limitations of the unconsidered costs (nephrotoxicity). This type of analysis contributes to rationalising the use of antifungal agents in the hospital setting and in high-risk patients such as oncohaematological ones.